This company is a mental health-focused organization dedicated to providing access to safe and affordable psychedelic-assisted therapy, primarily starting with ketamine therapy. As a fully integrated, pre-clinical stage biotech firm, they are committed to developing therapeutics for the accessible treatment of psychiatric diseases. The company focuses on conditions such as anxiety, depression, and dementia and is advancing a pipeline of high potential therapeutics designed to meaningfully improve neuropsychiatric care. The firm also incorporates immersive virtual environments to enhance the treatment of mental health. Additionally, they are developing neuroimaging systems to democratize the discovery, development, and treatment with emerging therapeutic agents. They have also created an intelligent, clinically accurate HRV wearable device for mental health and a digital companion app designed to support psychedelic therapy. In the field of professional education, the company offers programs in psychedelic-assisted psychotherapy and integration. They are an early-stage business incubator and accelerator focusing exclusively on the psychedelic sector. They are also a life sciences company focused on mushroom-derived medicines, developing psilocybin-based medicines while mitigating side effects, and working on the next generation of central nervous system drugs derived from psychedelics. Their mission extends to help solve the international opioid crisis with proven Ibogaine based clinical treatment protocols. They are also developing mushroom-based treatments aimed at opening new pathways to a healthier future. With a focus on elevating people's health and wellbeing, they are developing transformative consumer brands, products, and technologies. The company also invests in creating informed, honest, and transparent journalism that covers the integration of psychedelics into society and their broad implications for human wellness.